The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
Cognito Therapeutics
Creating non-invasive neuromodulation therapies to treat neurodegenerative diseases.
What they do
The company designs a non-invasive headset that delivers sensory stimulation using light and sound. The prescription therapy targets specific brain waves to slow down the progression of cognitive decline and brain atrophy in patients with mild Alzheimer's disease.
The record
- Vertical
- Neurotech
- Sub-segment
- Neuromodulation
- Product type
- Device
- Stage
- Series B
- Headquarters
- Cambridge, USA
- Region
- North America
- Founded
- 2016
- Total funding
- $93M raised
Notable investors: FoundersX Ventures, Starbloom Properties, IBB Ventures.
Also in Neurotech
Related on The Signal
Dr. Dereck Mush, MD, MBA
Next-Gen Neurotechnologies: Graphene Electrodes and Magnetic Surgical Robotics in Deep Brain Neuromodulation
Dr. Dereck Mush, MD, MBA
Neuroplasticity by Prescription: How Motivista Unlocks Negative Symptoms in Schizophrenia
Dr. Dereck Mush, MD, MBA
Medicare finally pays for prescription digital therapeutics, and the test begins
Dr. Dereck Mush, MD, MBA